Menu
Search
|

Menu

Close
X

Cardiome Pharma Corp CRME.OQ (NASDAQ Stock Exchange Capital Market)

1.45 USD
+0.00 (+0.00%)
As of Feb 16
chart
Previous Close 1.45
Open 1.45
Volume 5,432
3m Avg Volume 19,170
Today’s High 1.48
Today’s Low 1.45
52 Week High 4.83
52 Week Low 1.29
Shares Outstanding (mil) 33.80
Market Capitalization (mil) 67.53
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.67 Mean rating from 6 analysts

KEY STATS

Revenue (mm, USD)
FY17
17
FY16
25
FY15
21
EPS (USD)
FY17
-0.657
FY16
-0.791
FY15
-1.339
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
2.91
5.77
Price to Book (MRQ)
vs sector
2.39
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
98.56
16.52
LT Debt to Equity (MRQ)
vs sector
98.56
12.22
Return on Investment (TTM)
vs sector
-53.51
14.43
Return on Equity (TTM)
vs sector
-123.49
16.13

EXECUTIVE LEADERSHIP

W. James O'Shea
Independent Chairman of the Board, Since 2015
Salary: --
Bonus: --
William Hunter
President, Chief Executive Officer, Director, Since 2013
Salary: $669,500.00
Bonus: $669,500.00
Justin Renz
Chief Financial Officer, Since 2017
Salary: --
Bonus: --
Sheila Grant
Chief Operating Officer, Since 2013
Salary: $290,000.00
Bonus: $104,000.00
David McMasters
Corporate General Counsel, Since 2012
Salary: $397,440.00
Bonus: $143,078.00

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

1441 Creekside Dr 6th Floor
VANCOUVER   BC   V6J 4S7

Phone: +1604.6776905

Cardiome Pharma Corp. (Cardiome) is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of cardiovascular therapies for heart disease. The Company's segments are Europe and Rest of World. Cardiome has two marketed, in-hospital, cardiology products, which include BRINAVESS (vernakalant IV), approved in Europe and other territories for the conversion of onset atrial fibrillation (AF) to sinus rhythm in adults, and AGGRASTAT (tirofiban hydrochloride (HCl)), indicated for use in patients with acute coronary syndrome. Cardiome also commercializes ESMOCARD and ESMOCARD LYO (esmolol hydrochloride), a short-acting beta-blocker used to control heart rate in various cardiovascular indications, in select European markets. Cardiome has also licensed TREVYENT, a development-stage drug device combination product that is under development for pulmonary arterial hypertension, in certain regions outside the United States.

SPONSORED STORIES